The following table sets forth the computation of the basic and diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2022 and 2021 (in thousands, except share and per share amounts):

	Three Months Ended March 31,
	2022			2021
Net loss attributable to Adaptive Biotechnologies Corporation	$	(62,736	)	$	(40,642	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		141,697,252			138,967,754
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.44	)	$	(0.29	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three months ended March 31, 2022 and 2021 as they had an anti-dilutive effect:

	Three Months Ended March 31,
	2022		2021
Stock options outstanding		13,255,459		13,516,949
Nonvested restricted stock units		2,587,492		238,583
Maximum nonvested market-based restricted stock units eligible to be earned		153,762		—
Common stock warrant		—		34,757
Total		15,996,713		13,790,289